In conclusion, our findings reveal how PLK1-driven metabolic reprogramming enhances the adaptability of prostate cancer cells, particularly by modulating serine metabolism, glycolysis, and sphingolipid synthesis. The gene discussed is PLK1; the disease is prostate cancer.